The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
News|Articles|June 2, 2001
- Pharmaceutical Technology-06-02-2001
- Volume 25
- Issue 6
A Systematic Evaluation of the Compression and Tablet Characteristics of Various Types of Lactose and Dibasic Calcium Phosphate
Author(s)Ruey-ching (Richard) Hwang, PhD
Using formulations containing various types of lactose and dibasic calcium phosphate, the authors investigated the effects of lubricant level, lubrication time, and compression speed on tablet weight, hardness, and friability.
Advertisement
Articles in this issue
over 25 years ago
Viral Clearance Strategies for Biopharmaceutical Safetyover 25 years ago
Outsourcing Outlookover 25 years ago
Managing Risks and Resourcesover 25 years ago
Blister News: COC Resin, Foil, and Lidding Innovationsover 25 years ago
Managing the Risks in Outsourcingover 25 years ago
Systemic Drug Delivery via the Buccal Mucosal RouteAdvertisement
Related to this article
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
3
First-in-Human Trial Speed: Why FDA Trails China
4
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
5